Immunic (NASDAQ:IMUX) Receives Buy Rating from D. Boral Capital

Jan 7, 2025 · Immunic Trading Up 2.3 %. NASDAQ IMUX traded up $0.03 during trading hours on Tuesday, reaching $1.12. 518,288 shares of the company's stock were exchanged, compared …

$0.03
OFF

Immunic (NASDAQ:IMUX) Receives Buy Rating From D. Boral Capital

2 weeks from now

Jan 7, 2025 · Immunic Trading Up 2.3 %. NASDAQ IMUX traded up $0.03 during trading hours on Tuesday, reaching $1.12. 518,288 shares of the company's stock were exchanged, compared …

marketbeat.com

$17.00
OFF

Immunic, Inc. (NASDAQ:IMUX) Receives Consensus Rating Of "Buy" …

2 weeks from now

4 days ago · IMUX has been the subject of several research reports. D. Boral Capital reiterated a "buy" rating and issued a $17.00 target price on shares of Immunic in a research report on …

marketbeat.com

$1.10
OFF

Immunic (NASDAQ:IMUX) Given “Buy” Rating At D. Boral Capital

2 weeks from now

Jan 9, 2025 · IMUX stock opened at $1.10 on Tuesday. Immunic has a 1-year low of $0.97 and a 1-year high of $2.11. The business’s 50 day moving average is $1.14 and its 200-day moving …

etfdailynews.com

$1.10
OFF

Immunic (NASDAQ:IMUX) Earns “Buy” Rating From D. Boral Capital

2 weeks from now

Jan 9, 2025 · Shares of NASDAQ:IMUX opened at $1.10 on Tuesday. The firm has a market cap of $99.09 million, a price-to-earnings ratio of -0.89 and a beta of 1.88. Immunic has a 1 year …

defenseworld.net

$1.00
OFF

Immunic, Inc. (NASDAQ:IMUX) Given Average Rating Of “Buy” By …

2 weeks from now

Dec 23, 2024 · Shares of IMUX opened at $1.00 on Wednesday. The firm has a 50-day simple moving average of $1.24 and a two-hundred day simple moving average of $1.33. Immunic …

etfdailynews.com

$17.00
OFF

Immunic Stock Begins Coverage With A Buy Rating As Pivotal Trials ...

2 weeks from now

Sep 16, 2024 · On Monday, EF Hutton initiated coverage on Immunic Inc. (NASDAQ: IMUX), a biotechnology firm, with a Buy rating and a price target set at $17.00.The firm highlighted …

investing.com

$17
OFF

D. Boral Capital Maintains Buy On Immunic, Maintains $17 Price …

2 weeks from now

Jan 7, 2025 · D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ:IMUX) with a B... Invest Saudi Market. Stocks; ETFs; REITs; U.S. Market. ... D. Boral Capital Maintains Buy …

sahmcapital.com

$17.00
OFF

Immunic, Inc. (NASDAQ:IMUX) Receives Consensus Rating Of “Buy” …

2 weeks from now

4 days ago · IMUX has been the subject of several research reports. D. Boral Capital reiterated a “buy” rating and issued a $17.00 target price on shares of Immunic in a research report on …

mayfieldrecorder.com

90%
OFF

Immunic Inc. Buy D. Boral Capital - Sharewise

2 weeks from now

Jan 7, 2025 · This prediction is currently active. With a performance of -3.90%, the BUY prediction by D__Boral_Capital is trending in the wrong direction. This prediction currently runs until …

sharewise.com

12%
OFF

Immunic Stock (NASDAQ:IMUX): CEO Says "Right Time To Buy Now"

2 weeks from now

Aug 19, 2024 · Also, IMUX has a Moderate Buy consensus rating based on one Buy versus one Hold rating. Year-to-date, IMUX shares have declined 12%.See more IMUX analyst …

nasdaq.com

$13
OFF

Immunic CEO Says "Right Time" To Buy The Stock Is Now – Part 2

2 weeks from now

Sep 2, 2024 · On TipRanks, IMUX stock has a Moderate Buy consensus rating based on two Buys and one Hold recommendation. The average Immunic Therapeutics price target of $13 …

nasdaq.com

4%
OFF

Jane Street Group LLC Increases Position In Immunic, Inc.

2 weeks from now

1 day ago · Jane Street Group LLC lifted its position in shares of Immunic, Inc. (NASDAQ:IMUX – Free Report) by 121.4% in the 3rd quarter, according to the company in its most recent 13F …

etfdailynews.com

FAQs about Immunic (NASDAQ:IMUX) Receives Buy Rating from D. Boral Capital Coupon?

Should you buy immunic (IMUX) stock?

Immunic (NASDAQ:IMUX – Get Free Report) ‘s stock had its “buy” rating reissued by investment analysts at D. Boral Capital in a research report issued on Tuesday, Benzinga reports. They currently have a $17.00 price target on the stock. Other analysts have also recently issued reports about the company. ...

Should you buy immunic (IMUX – research report)?

Analyst William Wood of B.Riley Financial reiterated a Buy rating on Immunic (IMUX – Research Report), retaining the price target of $6.00. Unlock your investing potential with TipRanks Premium - Now At 40% OFF! William Wood has given his Buy rating due to a combination of factors that make Immunic an attractive investment opportunity. ...

Are institutional investors buying and selling immunic (IMUX) shares?

A number of institutional investors have recently bought and sold shares of IMUX. State Street Corp increased its holdings in shares of Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after acquiring an additional 11,642 shares during the last quarter. ...

What is the price target for immunic (IMUX)?

The highest price target for IMUX is $28.00, while the lowest price target for IMUX is $5.00. The average price target represents a forecasted upside of 982.57% from the current price of $1.09. Enter your email address to receive the latest news and analysts' ratings for Immunic and its competitors. ...

Who owns immunic stock?

Finally, Virtu Financial LLC acquired a new stake in Immunic during the third quarter worth approximately $50,000. 51.82% of the stock is owned by hedge funds and other institutional investors. (Get Free Report ...

Who owns IMUX stock?

Corporate insiders own 3.00% of the company’s stock. A number of institutional investors have recently bought and sold shares of IMUX. State Street Corp increased its holdings in shares of Immunic by 7.5% in the 3rd quarter. ...